Pentracor Gmbh

Theravision Gmbh

Birgit Vogt

Ahmed Sheriff

Ranjit Bhardwaj

Stephan Mattecka

Christopher Bock

The present invention relates to an apheresis device () for the extracorporeal removal of C-reactive protein from blood of a patient, wherein the apheresis device is connectable to the blood circulation of the patient. The blood is pumped via a part of the extracorporeal circulation system () of the apheresis device () according to the invention to a cell separator () for separation of the blood into blood plasma and cellular components. Via a first outlet of the cell separator (), the separated blood plasma is directed by means of a plasma line (A) to an apheresis column () for affinity chromatographic removal of C-reactive protein from the blood plasma. After removal of the C-reactive protein from the blood plasma of the patient, said now treated blood plasma is combined with the cellular components of the blood via a plasma line (B). Furthermore, the apheresis device () according to the invention comprises a bypass line (), which leads from the plasma line (A) into the plasma line (B) while bypassing the apheresis column (). The apheresis device () according to the invention also comprises a regeneration line (), which runs into the plasma line (A) or directly into the apheresis column ().

Simplified regeneration of apheresis columns

The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca-dependent) binding of CRP to a column material functionalized with &#x3c9;-phosphonooxyalkyl ammonium groups and/or with &#x3c9;-ammoniumalkoxy-hydroxy-phosphoryloxy groups.

Use of citrate solution for affinity chromatographic purification of CRP using phosphocholine and derivatives thereof

A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which

Compounds for neutralizing the effects of secreted PLA2 IIA

An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z, a Cys is present for forming the dimeric or multimeric protein,

Polypeptides and methods for making the same

An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence (I) with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z, a Cys is present for forming the dimeric or multimeric protein, Zis a signal peptide for protein transport to the ER and/or through the plasma membrane or NHor a derivative of an NHgroup such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Zis an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZwherein Zis hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms. 

Growing community of inventors

Berlin, Germany

Birgit Vogt